MX2009008334A - Esteroides que liberan oxido nitrico. - Google Patents

Esteroides que liberan oxido nitrico.

Info

Publication number
MX2009008334A
MX2009008334A MX2009008334A MX2009008334A MX2009008334A MX 2009008334 A MX2009008334 A MX 2009008334A MX 2009008334 A MX2009008334 A MX 2009008334A MX 2009008334 A MX2009008334 A MX 2009008334A MX 2009008334 A MX2009008334 A MX 2009008334A
Authority
MX
Mexico
Prior art keywords
formula
nitric oxide
oxide releasing
iii
group
Prior art date
Application number
MX2009008334A
Other languages
English (en)
Inventor
Ennio Ongini
Stefano Biondi
Francesa Benedini
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of MX2009008334A publication Critical patent/MX2009008334A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con un derivado nitrooxi de corticosteroides de fórmula general (I) y sales o estereoisómeros farmacéuticamente aceptables de los mismos; en donde R es el residuo del corticosteroide de fórmula (III): en donde: R1 es OH, R2-CH3, o R1 y R2 se toman juntos para formar un grupo de fórmula (III) R3 es Cl o F; R4 es H o F; en donde R1, R2, R3 y R4 pueden estar enlazados a los átomos de carbono correspondientes de la estructura esteroidal en la posición ? o ?; con la condición de que: cuando R1 y R2 son el grupo de fórmula (III), entonces R3 es F y R4 es H o F; los compuestos son útiles en el tratamiento de enfermedades respiratorias, enfermedades inflamatorias, enfermedades dermatológicas y enfermedades oculares.
MX2009008334A 2007-02-05 2008-01-28 Esteroides que liberan oxido nitrico. MX2009008334A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89937607P 2007-02-05 2007-02-05
US92945607P 2007-06-28 2007-06-28
PCT/EP2008/050938 WO2008095806A1 (en) 2007-02-05 2008-01-28 Nitric oxide releasing steroids

Publications (1)

Publication Number Publication Date
MX2009008334A true MX2009008334A (es) 2009-08-12

Family

ID=39232800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008334A MX2009008334A (es) 2007-02-05 2008-01-28 Esteroides que liberan oxido nitrico.

Country Status (15)

Country Link
US (4) US20100041633A1 (es)
EP (3) EP2109618A1 (es)
JP (1) JP5216782B2 (es)
KR (1) KR20090107525A (es)
CN (1) CN101652380A (es)
AU (1) AU2008213046B2 (es)
BR (1) BRPI0807078A2 (es)
CA (3) CA2677442A1 (es)
ES (1) ES2601102T3 (es)
IL (1) IL199815A (es)
MX (1) MX2009008334A (es)
NZ (1) NZ579067A (es)
RU (1) RU2442790C2 (es)
WO (3) WO2008095808A1 (es)
ZA (1) ZA200905067B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011132171A1 (en) 2010-04-23 2011-10-27 Piramal Life Sciences Limited Nitric oxide releasing prodrugs of therapeutic agents
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
CN104010626A (zh) 2011-10-12 2014-08-27 阿森迪斯药物眼科部股份有限公司 眼病症的预防和治疗
EP2862600B1 (en) * 2011-12-20 2020-02-12 Oriflame Research and Development Ltd. Compounds with Anti-aging activities
AU2013328774B2 (en) 2012-10-11 2017-11-30 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
WO2014111957A1 (en) 2013-01-21 2014-07-24 Apparao Satyam Nitric oxide releasing prodrugs of therapeutic agents
RU2545416C1 (ru) * 2014-02-18 2015-03-27 Ксения Юрьевна Еременко Способ лечения возрастной макулярной дистрофии
CN103880907A (zh) * 2014-03-11 2014-06-25 天津金耀集团有限公司 丁酸氢化可的松半水合物
SG10202104259RA (en) 2016-11-08 2021-06-29 Regeneron Pharma Steroids and protein-conjugates thereof
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
SG11202010909RA (en) 2018-05-09 2020-12-30 Regeneron Pharma Anti-msr1 antibodies and methods of use thereof
US11059789B2 (en) * 2018-08-31 2021-07-13 Aerie Pharmaceuticals, Inc. Isoquinoline-steroid conjugates and uses thereof
WO2022135332A1 (zh) * 2020-12-21 2022-06-30 映恩生物制药（苏州）有限公司 一种甾体偶联物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3183252A (en) 1963-09-05 1965-05-11 Syntex Corp 16-nitratoalkyl-pregnanes
US3494941A (en) * 1967-12-04 1970-02-10 American Home Prod Nitrate esters of 17beta-(hydroxyalkoxy)steroid 3-ols,3-ones and 3-amidinohydrazones
HU164115B (es) 1971-05-07 1973-12-28
IT1285770B1 (it) * 1996-10-04 1998-06-18 Nicox Sa Composti corticoidei
IT1311922B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CN101300265A (zh) * 2005-09-02 2008-11-05 尼科克斯公司 糖皮质激素硝酰氧基衍生物

Also Published As

Publication number Publication date
WO2008095806A1 (en) 2008-08-14
CA2677290A1 (en) 2008-08-14
CN101652380A (zh) 2010-02-17
EP2109617A1 (en) 2009-10-21
ES2601102T3 (es) 2017-02-14
EP2118120A1 (en) 2009-11-18
CA2677441C (en) 2016-04-12
US20150105547A1 (en) 2015-04-16
IL199815A (en) 2015-03-31
JP5216782B2 (ja) 2013-06-19
CA2677441A1 (en) 2008-08-14
WO2008095809A1 (en) 2008-08-14
IL199815A0 (en) 2010-04-15
CA2677442A1 (en) 2008-08-14
AU2008213046A1 (en) 2008-08-14
US8933062B2 (en) 2015-01-13
ZA200905067B (en) 2010-04-28
US20100234334A1 (en) 2010-09-16
AU2008213046B2 (en) 2013-02-14
NZ579067A (en) 2012-02-24
EP2109618A1 (en) 2009-10-21
JP2010517955A (ja) 2010-05-27
RU2442790C2 (ru) 2012-02-20
US20100041633A1 (en) 2010-02-18
US20100093685A1 (en) 2010-04-15
WO2008095808A1 (en) 2008-08-14
RU2009132993A (ru) 2011-03-20
BRPI0807078A2 (pt) 2014-04-08
EP2118120B1 (en) 2016-10-05
KR20090107525A (ko) 2009-10-13

Similar Documents

Publication Publication Date Title
MX2009008334A (es) Esteroides que liberan oxido nitrico.
WO2010089303A9 (en) CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
WO2009075835A8 (en) CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
NZ594210A (en) Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
NZ700195A (en) Compositions comprising deoxycholic acid
SG10201809638YA (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
WO2010127237A3 (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
IL183696A0 (en) Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
RS20110548A1 (en) TETRACYCLIC UNITS
CL2008001982A1 (es) Acido (2s)-2-{[3´-cloro-4´-[2,2-dimetilpirrolidin-1-il) carbonil]-5-fluorobifenil-2-il]oxi}propanoico y su sal 2-metilpropan-2-amina; formas cristalinas de la sal y del acido libre; compuestos intermediarios; y uso en el tratamiento de asma, rinitis y enfermedad pulmonar obstructiva cronica.
NZ719360A (en) Preparation, uses and solid forms of obeticholic acid
JP2008546694A5 (es)
EP2749283A3 (en) Combination of glycopyrronium and olodaterol
HUE036410T2 (hu) Pregnán és androsztán szteroidok alkalmazása CNS rendellenességek kezelésére szolgáló gyógyszerkészítmény elõállítására
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
JP2010510210A5 (es)
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
MX336505B (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
PH12015501100B1 (en) Novel compounds
UA92324C2 (en) Novel 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17я-hydroxysteroid dehydrogenase type 1
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
UA86807C2 (ru) ПОРОШКОВАЯ КОМПОЗИЦИЯ ДЛЯ ИНГАЛЯЦИИ, КОТОРАЯ СОДЕРЖИТ ЭНАНТИОМЕРНО ЧИСТЫЕ β-АГОНИСТЫ
TN2012000077A1 (en) Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
WO2009099998A3 (en) Therapeutic treatment for lung conditions

Legal Events

Date Code Title Description
FG Grant or registration